Adma Biologics (ADMA) Cash & Equivalents (2011 - 2026)

Adma Biologics (ADMA) has 15 years of Cash & Equivalents data on file, last reported at $87.6 million in Q4 2025.

• Quarterly Cash & Equivalents fell 15.04% year-over-year to $87.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $87.6 million (down 15.04% YoY) and the FY2025 annual result came in at $87.6 million, down 15.04% from the prior year.
• Cash & Equivalents advanced to $87.6 million in Q4 2025, from $61.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $103.1 million in Q4 2024 to a low of $34.4 million in Q3 2021.
• A 5-year average of $66.2 million and a median of $65.9 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2021 — Cash & Equivalents slumped 42.35% — and 2023, when it jumped 112.57%.
• Tracing ADMA's Cash & Equivalents over 5 years: stood at $51.1 million in 2021, then jumped by 69.36% to $86.5 million in 2022, then slumped by 40.65% to $51.4 million in 2023, then surged by 100.86% to $103.1 million in 2024, then decreased by 15.04% to $87.6 million in 2025.
• The last three Cash & Equivalents figures came in at $87.6 million (Q4 2025), $61.4 million (Q3 2025), and $90.3 million (Q2 2025), per Business Quant data.